Innovent Biologics, Inc. (HKG:1801)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
50.25
+0.40 (0.80%)
Apr 3, 2025, 4:08 PM HKT

Innovent Biologics Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2016 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
Cash & Equivalents
7,50810,0529,1638,3777,764
Upgrade
Short-Term Investments
375.56----
Upgrade
Trading Asset Securities
-917.533.21638.21357.3
Upgrade
Cash & Short-Term Investments
7,88410,9709,1669,0158,121
Upgrade
Cash Growth
-28.13%19.68%1.67%11.01%72.97%
Upgrade
Accounts Receivable
1,1841,006575.27968.41475.38
Upgrade
Other Receivables
----91.72
Upgrade
Receivables
1,1841,006575.27975.91575.2
Upgrade
Inventory
822.17968.091,4291,347705.66
Upgrade
Other Current Assets
382.52484.38336.52212.464.69
Upgrade
Total Current Assets
10,27313,42811,50711,5519,467
Upgrade
Property, Plant & Equipment
5,6474,6563,8263,0901,911
Upgrade
Long-Term Investments
3,626794.09630.2417.2612.94
Upgrade
Other Intangible Assets
1,28327.7930.0519.75-
Upgrade
Long-Term Deferred Charges
-1,2421,168752.4532.63
Upgrade
Other Long-Term Assets
774.02478.64427.63412.07410.15
Upgrade
Total Assets
21,60320,62717,58916,24411,835
Upgrade
Accounts Payable
357.68372.55325.62195.05120.62
Upgrade
Accrued Expenses
-2,1561,5171,678819.95
Upgrade
Current Portion of Long-Term Debt
405.11,195888365255
Upgrade
Current Portion of Leases
8.8325.1826.3922.2716.16
Upgrade
Current Income Taxes Payable
--3.360.59-
Upgrade
Current Unearned Revenue
256.41416.17434.91355.51120.44
Upgrade
Other Current Liabilities
3,341312.16303.71374.05153.69
Upgrade
Total Current Liabilities
4,3694,4773,4993,0501,486
Upgrade
Long-Term Debt
2,4122,3272,2152,023925.18
Upgrade
Long-Term Leases
4.7673.4298.6886.3910.23
Upgrade
Long-Term Unearned Revenue
1,215960.05883.28753.27633.96
Upgrade
Other Long-Term Liabilities
483.82262.71162.310.34-
Upgrade
Total Liabilities
8,4858,1006,8595,9133,055
Upgrade
Common Stock
0.110.110.110.10.1
Upgrade
Additional Paid-In Capital
-27,32424,70622,49418,541
Upgrade
Retained Earnings
--15,768-14,740-12,560-9,982
Upgrade
Comprehensive Income & Other
13,118970.54763.86397.02220.41
Upgrade
Total Common Equity
13,11812,52810,73010,3308,780
Upgrade
Shareholders' Equity
13,11812,52810,73010,3308,780
Upgrade
Total Liabilities & Equity
21,60320,62717,58916,24411,835
Upgrade
Total Debt
2,8313,6213,2292,4971,207
Upgrade
Net Cash (Debt)
5,0537,3495,9386,5186,915
Upgrade
Net Cash Growth
-31.25%23.77%-8.91%-5.73%80.53%
Upgrade
Net Cash Per Share
3.104.713.984.485.10
Upgrade
Filing Date Shares Outstanding
1,6321,6221,5341,4621,403
Upgrade
Total Common Shares Outstanding
1,6321,6221,5341,4621,403
Upgrade
Working Capital
5,9048,9518,0088,5017,981
Upgrade
Book Value Per Share
8.047.726.997.076.26
Upgrade
Tangible Book Value
11,83512,50010,70010,3118,780
Upgrade
Tangible Book Value Per Share
7.257.716.977.056.26
Upgrade
Buildings
-402.67402.46389.73389.73
Upgrade
Machinery
-2,6582,5231,4201,183
Upgrade
Construction In Progress
-2,1421,1391,293287.66
Upgrade
Leasehold Improvements
-121.82107.66106.8576.76
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.